Star Therapeutics

Private

#Rare Disease #Hematology #Bleeding Disorders #Immunology

South San Francisco biotech built on a hub-and-spoke model that incubates antibody companies in bleeding disorders and immunology, most notably Vega Therapeutics (VGA039, sold to Incyte in 2026) and ELECTRA Therapeutics.

Company Info

Sector:Biotechnology — Antibody Therapeutics

Headquarters:South San Francisco, CA, USA

Founded:2018

Website:star-therapeutics.com/

Funding Round:$200 million private financing (October 2026)

Total Funding:~$325 million or more, including a $125 million Series D (September 2025)

Funding & Investor Relations

IPO Outlook / Plans

Has publicly weighed an IPO but has continued to fund itself privately

Clinical Development Pipeline

VGA039

Target: Protein S

von Willebrand disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Adam Rosenthal, Ph.D.

Founder, Chief Executive Officer and Board Chair

Sandip Panicker, Ph.D.

Chief Scientific Officer

Scott Robertson

Chief Business Officer and Chief Financial Officer

Careers & Job Openings

See all open roles

All

South San Francisco, CA

Apply Now →